NCCN Optimizing Patient Outcomes - Management of Bispecific T-Cell Engager Toxicities: How to Balance Increased Efficacy with Notable Toxicity

October 16, 2026
Managing BsAb toxicity requires an interprofessional approach including advanced practitioners, clinical pharmacy specialists, and access to medical specialists in relevant disciplines. Understanding the potential toxicities is crucial for safe and effective use. All the members of the health care team should receive proper education and training regarding BsAb toxicity to understand how to maximize the therapeutic benefits and minimize the potential risks. Optimizing patient outcomes requires care coordination and communication as well as an institution-specific standard operating procedure to prevent morbidity and mortality from BsAbs.
 
Click here to download more information to share with your colleagues!

Target Audience

This program is designed to meet the educational needs of physicians, nurses, nurse practitioners, pharmacists, physician associates and other health care professionals who treat patients with cancer.  

Learning Objectives

Following this activity, participants should be able to:

  • Outline implementation of an interprofessional standard operating procedure for evaluating product-specific site of care administration and managing bispecific antibody toxicity in clinic and at home.
  • Choose appropriate infection prophylaxis strategies for patients on BsAbs.
  • Outline a comprehensive therapeutic plan for patient education on signs and symptoms of CRS and ICANS, including recognizing early signs of toxicities and when to seek medical attention.

You may also be interested in

Maximizing Benefit, Minimizing Risk: Managing Immune Checkpoint Inhibitor Toxicities

The landscape of cancer care has undergone a dramatic shift due to the emergence of immune checkpoint inhibitors (ICIs).
Monitoring Toxicities in the Ambulatory Setting

The landscape of cancer care has undergone a dramatic shift due to the availability and increased use of immunotherapy and targeted agents.
Additional information
Supporters: 

Supported by educational grants from:

  • Johnson & Johnson
  • Genentech, a member of the Roche Group

This activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.

Course summary

Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
    • 1.00 ANCC Pharmacology Contact Hours
  • 1.00 Participation
Course opens: 
07/08/2026
Course expires: 
01/04/2027
Event starts: 
10/16/2026 - 10:00am EDT
Event ends: 
10/16/2026 - 11:00am EDT
Part of: 
NCCN Webinar Series - Optimizing Patient Outcomes: Collaborative Perspectives in Oncology
Add to calendar: 
Presenters
 
Patricia Mangan, MSN, RN, APRN-BC, CRNP
Abramson Cancer Center at the University of Pennsylvania
 
Oxana Megherea, PharmD, BCOP
Abramson Cancer Center at the University of Pennsylvania
 
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
 
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 
 
Definitions
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
 
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery. Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
 
Faculty Disclosures
The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
 
Patricia Mangan, MSN, RN, APRN-BC, CRNP
GSK: Product/Speakers Bureau
Johnson & Johnson: Product/Speakers Bureau
Karopharm Therapeutics: Product/Speakers Bureau
 
Oxana Megherea, PharmD, BCOP
Janssen Pharmaceuticals Products, LP: Consulting Fee
Pfizer, Inc.: Consulting Fee
 
NCCN Staff Disclosures
None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing health care products by or on patients.
image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians
NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour. This activity offers 1.0 pharmacotherapeutic contact hour for nurses.

Pharmacists
NCCN designates this application-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-26-078-L01-P

PAs
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
    • 1.00 ANCC Pharmacology Contact Hours
  • 1.00 Participation
Please login or register to take this course.

Click Take Course to claim credit for the webinar.

  • This webinar was presented live one time only on Friday, October 16, 2026.
  • Unable to attend the live webinar? The recorded presentation will be available in ~1 week at education.nccn.org/outcomes2026. 
  • To adjust for other time zones, click here.

NCCN Non-Discrimination/Harassment Policy – Affiliated Persons and Volunteers
NCCN is committed to providing workplaces and events that are free from discrimination or harassment of any kind for all participants, and has a zero-tolerance policy for any such conduct. NCCN requires individuals participating on NCCN Guidelines Panels, standing and ad hoc committees, meetings and seminars, or other NCCN-affiliated activities and events to adhere to this policy.

To access this policy including reporting procedures, please visit NCCN.org/non-discrimination.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability (speakers or a headset) 
  • Adobe Reader or other PDF reader software for certificate viewing/printing